CYADY — Celyad Oncology SA Income Statement
0.000.00%
- $16.86m
- $12.17m
Annual income statement for Celyad Oncology SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 3.12 | 0.006 | 0.005 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 3.12 | 0.006 | 0.005 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 41.3 | 28.9 | 17 | 26.4 | 40.9 |
Operating Profit | -38.2 | -28.9 | -17 | -26.4 | -40.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -37.4 | -28.6 | -17.2 | -26.5 | -40.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -37.4 | -28.6 | -17.2 | -26.5 | -40.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -37.4 | -28.6 | -17.2 | -26.5 | -40.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -37.4 | -28.6 | -17.2 | -26.5 | -40.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.36 | -2.29 | -1.23 | -1.7 | -0.802 |
Dividends per Share |